Eyenovia (NASDAQ:EYEN) Earns Market Perform Rating from William Blair

Eyenovia (NASDAQ:EYEN)‘s stock had its “market perform” rating reaffirmed by equities research analysts at William Blair in a research note issued on Friday,Benzinga reports. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Wednesday.

Eyenovia Trading Down 70.0 %

Shares of NASDAQ EYEN opened at $0.10 on Friday. The firm has a 50 day moving average price of $0.49 and a two-hundred day moving average price of $0.71. The stock has a market cap of $6.53 million, a P/E ratio of -0.14 and a beta of 1.75. Eyenovia has a 52-week low of $0.09 and a 52-week high of $2.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.27 and a current ratio of 0.74.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the business earned ($0.18) earnings per share. As a group, equities analysts forecast that Eyenovia will post -0.56 EPS for the current year.

Insider Activity at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. The trade was a 151.85 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eyenovia

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares during the period. Nations Financial Group Inc. IA ADV increased its stake in shares of Eyenovia by 78.6% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after acquiring an additional 40,000 shares in the last quarter. Financial Management Network Inc. acquired a new position in shares of Eyenovia during the 3rd quarter valued at $39,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eyenovia during the second quarter worth $26,000. Finally, SkyView Investment Advisors LLC bought a new position in Eyenovia during the second quarter worth $87,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.